Tom Cavanaugh is a results-focused leader who has an outstanding ability to navigate through complex environments, grow talent and inspire teams to achieve new possibilities. Recently appointed as the Company Group Chairman, North America, Tom is a member of the Innovative Medicine Group Operating Committee and responsible for leading our efforts to transform the health of people in the U.S. and Canada who face a range of common and rare, complex diseases across our areas of focus.
Prior to his new appointment, Tom was Company Group Chairman, Global Commercial Strategy Organization, and led the development of our commercial strategy for pipeline and in-market assets in close collaboration with R&D, Business Development, and Commercial leaders around the world. This included a robust evaluation of our portfolio and external innovation opportunities, enabling us to invest deeply where we are poised to have the greatest impact.
Tom has a 27-year career in the industry. He joined J&J in 2017 as President of U.S. Oncology and led the organization to become the industry’s fastest-growing multibillion-dollar oncology business. Later as President of U.S. Immunology, Tom led his team to deliver all-time high business results through the COVID pandemic.
Prior to joining J&J, Tom helped build Celgene into a global biopharmaceutical company through leadership positions in marketing, general management, medical affairs and product development. Early in his career, Tom held roles in sales, product management and as a chemist and pharmacy tech after receiving a Bachelor’s in Chemistry from North Carolina State University.